ArticleBMC ophthalmology2026
Twelve-month lesion reactivation after initial loading injections of faricimab in neovascular AMD: a comparison between three and four loading injections.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe incidence and timing of first lesion reactivation following initial loading injections of faricimab for neovascular age-related macular degeneration (AMD) were assessed, and factors related to lesion reactivation were analyzed.
methodsThis retrospective study included patients with treatment-naive neovascular AMD who underwent either three or four monthly loading injections of faricimab and completed 12 months of follow-up. The incidence and timing of the first lesion reactivation following the initial loading phase were analyzed and compared between the two treatment groups (three-injection and four-injection groups). In addition, the baseline parameters associated with the risk of lesion reactivation were investigated.
resultsSeventy-seven patients were included in the study (35 in the three-injection group and 42 in the four-injection group). Lesion reactivation was observed in 72.7% of patients (56 patients) at a mean of 5.1 ± 2.3 months after the loading injections. The incidence was 74.3% with a mean time to reactivation of 5.6 ± 2.9 months in the three-injection group; it was 71.4% with a mean of 4.6 ± 1.7 months in the four-injection group. No significant difference was noted in lesion reactivation between the two groups (P = 0.983). A greater baseline central retinal thickness was significantly associated with an increased risk of lesion reactivation (P = 0.010).
conclusionsAdministering four loading injections of faricimab may not offer a clear advantage over three injections in suppressing lesion reactivation. A treat-and-extend regimen may be more appropriate in cases with marked retinal edema than an as-needed regimen to prevent further visual deterioration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.